Literature DB >> 7982731

Impact of intravenous infusions of low and high doses of gamma globulins (IVIG) on phagocytic functions in adults with primary humoral immunodeficiency.

T Van1, G Sussman, W Pruzanski.   

Abstract

Twelve adult patients with primary humoral immunodeficiency were treated for at least six months with IVIG 200 mg/kg/mo and then crossed over to a high dose of 600 mg/kg/mo. Polymorphonuclear and mononuclear cells of these patients were tested after the third infusion in the low-dose cycle and then after the third infusion in the high-dose cycle, each time a day before, four days after, and 14 days after intravenous infusion. Each time, patients' cells and normal cells were tested using normal sera and patients' sera. IVIG infusions led to a significant increase in the level of circulating IgG, which was much more prominent in the high-dose group. Phagocytosis, phagocytic index, intracellular bactericidal activity and chemotaxis of polymorphonuclear cells (PMNs) were at least as active as in healthy controls. Actually in both cycles patients' PMN's had slightly higher phagocytic activity than normal cells. Patients' serum in the high dose cycle supported chemotaxis better than normal serum. Efficient phagocytic activity was maintained throughout the cycle; however, it was more active (P < 0.0125) in the midcycle in the high-dose cycle. Superoxide generation was normal in all conditions. Monocytic function was also normal in all conditions tested. It may be concluded that as far as cellular phagocytic functions are concerned, the high dose of IVIG does not protect the host more efficiently than the low dose.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7982731     DOI: 10.1007/BF01534439

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  9 in total

1.  Modulation of functional activity of human polymorphonuclear and mononuclear phagocytes by intravenous gamma globulin.

Authors:  W Pruzanski; S Saito
Journal:  Inflammation       Date:  1989-06       Impact factor: 4.092

2.  Immunoglobulins as aspecific opsonins. II. The influence of specific and aspecific immunoglobulins on the in vitro phagocytosis of noncapsulated, capsulated, and decapsulated bacteria by human neutrophils.

Authors:  M W Stinson; C J Van Oss
Journal:  J Reticuloendothel Soc       Date:  1971-05

Review 3.  Clinical uses of intravenous immunoglobulins.

Authors:  S A Berkman; M L Lee; R P Gale
Journal:  Ann Intern Med       Date:  1990-02-15       Impact factor: 25.391

4.  Immunoglobulins as aspecific opsonins. I. The influence of polyclonal and monoclonal immunoglobulins on the in vitro phagocytosis of latex particles and Staphylococci by human neutrophils.

Authors:  C J Van Oss; M W Stinson
Journal:  J Reticuloendothel Soc       Date:  1970-11

5.  Comparative opsonic activity of intravenous gamma globulin preparations for common bacterial pathogens.

Authors:  H R Hill; N H Augustine; A O Shigeoka
Journal:  Am J Med       Date:  1984-03-30       Impact factor: 4.965

6.  Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases.

Authors:  H D Ochs; S H Fischer; R J Wedgwood; D W Wara; M J Cowan; A J Ammann; A Saxon; M D Budinger; R U Allred; R H Rousell
Journal:  Am J Med       Date:  1984-03-30       Impact factor: 4.965

7.  Intravenous immune globulin for hypogammaglobulinemia: a comparison of opsonizing capacity in recipient sera.

Authors:  R W Steele; R A Augustine; A S Tannenbaum; D J Marmer
Journal:  Clin Immunol Immunopathol       Date:  1985-03

8.  Results of a prospective controlled two-dose crossover study with intravenous immunoglobulin and comparison (retrospective) with plasma treatment.

Authors:  E Bernatowska; K Madaliński; W Janowicz; R Weremowicz; P Gutkowski; H M Wolf; M M Eibl
Journal:  Clin Immunol Immunopathol       Date:  1987-05

Review 9.  Intravenous immunoglobulin: a review.

Authors:  M M Eibl; R J Wedgwood
Journal:  Immunodefic Rev       Date:  1989
  9 in total
  1 in total

1.  Modulatory Effects of Antibody Replacement Therapy to Innate and Adaptive Immune Cells.

Authors:  Isabella Quinti; Milica Mitrevski
Journal:  Front Immunol       Date:  2017-06-16       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.